1. Abstract
AIM Dysmenorrhea, defined as pain during menstruation, is the most common gynecological condition, affecting a large percentage of women with varying degrees of pain. In recent years, the management of dysmenorrhea has become increasingly important because of the emotional, health and economic burden it entails and because of the need for new studies and research for effective treatments to alleviate its symptoms. The most common treatments for dysmenorrhea are NSAIDs or oral contraceptives, although gynecologists also recommend the preparation composed of N-acetyl cysteine (NAC), alpha lipoic acid (LA), bromelain (Br) and Zinc (Zn), (NAC/LA/Br/Zn) due to its anti-inflammatory and anti-oxidative properties and efficacy in reducing pain. However, there is no data on what dosage of the preparation should be recommended for patients with dysmenorrhea. Therefore, the aim of this study is to determine how the NAC/LA/Br/Zn preparation is recommended for the treatment of dysmenorrhea in daily clinical practice and what specialists base their decision on.
Methods and Results A survey was conducted among gynecologists with extensive experience recommending the preparation, with a participation rate of 97% (N=73). The most frequently recommended regimen is to begin with continuous administration for 90 days with 10-day breaks (69%) or without breaks (31%). Specialists recommend the preparation for any type of pain and may recommend discontinuous administration (in the days around menstruation) when the pain is moderate or mild. In patients with primary dysmenorrhea with mild pain, the most recommended approach is discontinuous therapy in the days around menstruation (50.7%) followed by continuous administration for 90 days with 10-day breaks (24.7%). When pain is moderate or severe, the most recommended approach is 90-day continuous therapy with 10-day breaks (47.9% and 71.2%, respectively). In the case of secondary dysmenorrhea, the most recommended approach is 90-day continuous therapy with 10-day breaks for any degree of pain (41.1%, 57.5% and 76.7% for mild, moderate and severe pain, respectively). Most gynecologists (79%) adapt the regimen after clinical assessment of the degree of pain towards discontinuous administration patterns, on the days around menstruation. Most of the specialists consulted do not modify the recommended regimen if the patient is being treated with other drugs such as NSAIDs, hormonal contraception or a combination of progestogens (78%, 59% and 58%, respectively). The preparation is recommended in conjunction with hygienic-dietary measures without modification of the dosage (90%).
Conclusion This is the first study that addresses how specialists recommend the NAC/LA/Br/Zn preparation to patients with dysmenorrhea. The most common regimen for dysmenorrhea is to start treatment with continuous administration of the preparation for 90 days with 10 days of break, continuing the regimen or adapting it according to the degree of pain reported by the patient during treatment.
- Dysmenorrhea
- N-Acetyl cysteine
- Alpha lipoic acid
- Bromelain
- Zinc
- Antioxidants
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Adamed Spain S.L.U, who was not involved in the design of the study, and data collection or interpretation. The funding includes medical writing of the manuscript and the article processing charges.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
